The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of liraglutide for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin; it also reduces the appetite and therefore food intake by slowing gastric emptying. In preliminary recommendations published today (15 February 2010), NICE has recommended liraglutide 1.2 mg daily as part of triple therapy regimens (in combination with metformin and sulfonylurea, or metformin and a thiazolidinedione) as an option for the treatment of type 2 diabetes, when control of blood glucose remains or becomes inadequate (HbA1c â 7.
In type 2 diabetes, which is occurring at alarming rates, the hormone insulin does not work effectively to lower blood sugars and patients also do not make enough insulin. These two processes have been widely considered as separate. However, a surprising discovery was made by Joslin Diabetes Center researchers in animal models of diabetes: insulin is important in regulating its own production. Confirming this discovery, Joslin clinical scientists have now gone on to show that when blood sugar levels rise in healthy people, insulin signals the cells that make insulin to increase their production. Our bodies absorb sugar when we eat carbohydrates, and insulin acts as a "key" for the sugar to get into cells, where it provides energy for the cells to function.
Care for people with diabetes has continued to improve according to a report published today by the Department of Health. The sixth annual update on progress with diabetes care recognises key achievements made in the last year including completion of the first survey to establish how many children and young people have diabetes in England. Six Years On: Delivering the Diabetes National Service Framework updates progress made since the NSF for Diabetes was developed in 2001, setting out national standards of care for people with diabetes. The survey of children and young people with diabetes undertaken last year was an important project carried out in partnership with the Royal College of Paediatric and Child Health, NHS Diabetes Information Service and many other stakeholders.
New research by University of Cincinnati (UC) scientists implicates a new protein in obesity development and highlights a protein pair's "team effort" in regulating obesity and insulin resistance. Jorge Moscat, PhD, chair of UC's cancer and cell biology department, says that proteins p62 and ERK are involved in adipogeneis, (the development of adipocytes, or fat cells). His new study shows precisely how this duo works together. The study is published online in advance of print Friday, Feb. 12, 2010, in the journal EMBO Reports, and will appear in print in the March 1, 2010, edition. Earlier research led by Moscat showed that removing or "knocking out" p62 in mice led to the development of obesity and insulin resistance in adulthood.
IDF reinforces its support to translational research in diabetes with the second round of its funding programme, BRIDGES (Bringing Research in Diabetes to Global Environments and Systems). Nine new diabetes research projects will be funded for a total of US$2 million over the next three years as part of the International Diabetes Federation's (IDF) translational research grant programme, BRIDGES. A total of 157 applications were considered for the second round of funding. The chosen projects address important issues in primary and secondary prevention of diabetes in different parts of the world. "BRIDGES is a key programme for IDF's work and mission.
Biodel To Present Results From VIAject R Phase 3 Studies At Advanced Technologies And Treatments For Diabetes Conference In Basel
Biodel, Inc. (Nasdaq: BIOD) announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company's two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time. The presentation, entitled "Clinical Findings for Patients Treated with VIAject® , An Ultra-Rapid Acting Formulation of Recombinant Human Insulin, " will review and update key data from the VIAject® clinical development program.